U.S. FDA approves SIMPONI® (golimumab) for the treatment of pediatric ulcerative colitis

HORSHAM, Pa. (October 7, 2025) – Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI® (golimumab) for the treatment of children living with moderately to…